Traick
Product

A published scale, not a proprietary one.

Traick’s scoring is ACR TI-RADS: the peer-reviewed system radiologists already use, applied consistently and shown in full. Below is exactly how each of the five criteria is scored, category by category, the same table a radiologist would use by hand.

Five features. Every one independently scored. No criterion is weighted by feel: each has a fixed, published point value.

The table is live: click any row and the nodule on the right follows.

01Composition

points

02Echogenicity

points

03Shape

points

04Margin

points

05Echogenic foci

points, cumulative

Echogenic foci is the one category where more than one finding can apply to the same nodule; its points add together. The other four categories use the single highest-scoring option present.

TR4 · Moderately Suspicious4pts

Schematic nodule, redrawn from your choices

2+2+0+0+0=4TR4 · Moderately Suspicious

TR1

0

TR2

2

TR3

3

TR4

4–6

TR5

≥ 7

1.7 cm

At or above the ACR FNA size threshold for TR4 (≥ 1.5 cm)

Educational illustration of the published point table. Simplified: the ACR white paper has further notes per category. Not for clinical use.

Clinical Basis

The five points sum to one total. That total places the nodule into TR1 through TR5, with its own FNA threshold.

CategoryPointsFNA threshold
TR1 · Benign0No FNA
TR2 · Not Suspicious2No FNA
TR3 · Mildly Suspicious3≥ 2.5 cm
TR4 · Moderately Suspicious4–6≥ 1.5 cm
TR5 · Highly Suspicious≥ 7≥ 1 cm

Point bands and FNA size thresholds above are the ACR TI-RADS values, not Traick’s own. Our job is to apply them consistently and show the arithmetic. The decision to biopsy remains a clinical judgment.

What This Scale Doesn’t Do

Ultrasound features, and nothing else. TI-RADS estimates malignancy risk from imaging appearance alone.

It does not incorporate patient history, prior cytology, family history or genetic markers, and it does not replace clinical judgment. Traick doesn’t either: the score is a structured starting point for the radiologist’s own assessment, not a substitute for it.

  • Patient history
  • Prior cytology
  • Family history
  • Genetic markers

Request a Demo

Talk to your IT team? We’re happy to join that conversation.